These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1732038)

  • 1. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.
    Adamson PC; Balis FM; Miser J; Arndt C; Wells RJ; Gillespie A; Aronson L; Penta JS; Clendeninn NJ; Poplack DG
    Cancer Res; 1992 Feb; 52(3):521-4. PubMed ID: 1732038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.
    Adamson PC; Balis FM; Miser J; Wells RJ; Bleyer WA; Williams TE; Gillespie A; Penta JS; Clendeninn NJ; Poplack DG
    Cancer Res; 1990 Aug; 50(15):4464-7. PubMed ID: 2369724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
    Kitchen BJ; Balis FM; Poplack DG; O'Brien M; Craig CE; Adamson PC
    Clin Cancer Res; 1997 May; 3(5):713-7. PubMed ID: 9815740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of everolimus in pediatric patients with refractory solid tumors.
    Fouladi M; Laningham F; Wu J; O'Shaughnessy MA; Molina K; Broniscer A; Spunt SL; Luckett I; Stewart CF; Houghton PJ; Gilbertson RJ; Furman WL
    J Clin Oncol; 2007 Oct; 25(30):4806-12. PubMed ID: 17947729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study.
    Adamson PC; Widemann BC; Reaman GH; Seibel NL; Murphy RF; Gillespie AF; Balis FM
    Clin Cancer Res; 2001 Oct; 7(10):3034-9. PubMed ID: 11595692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate.
    McDonald AC; Vasey PA; Adams L; Walling J; Woodworth JR; Abrahams T; McCarthy S; Bailey NP; Siddiqui N; Lind MJ; Calvert AH; Twelves CJ; Cassidy J; Kaye SB
    Clin Cancer Res; 1998 Mar; 4(3):605-10. PubMed ID: 9533527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies.
    Feun LG; Savaraj N; Benedetto P; Hanlon J; Sridhar KS; Collier M; Richman S; Liao SH; Clendeninn NJ
    J Natl Cancer Inst; 1991 Jan; 83(1):51-5. PubMed ID: 1984518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.
    Feun LG; Gonzalez R; Savaraj N; Hanlon J; Collier M; Robinson WA; Clendeninn NJ
    J Clin Oncol; 1991 Mar; 9(3):464-7. PubMed ID: 1999717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
    Lowis SP; Pearson AD; Newell DR; Cole M
    Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
    de Vries EG; Gietema JA; Workman P; Scott JE; Crawshaw A; Dobbs HJ; Dennis I; Mulder NH; Sleijfer DT; Willemse PH
    Br J Cancer; 1993 Sep; 68(3):641-4. PubMed ID: 8353055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
    Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
    Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
    Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.
    Malempati S; Nicholson HS; Reid JM; Blaney SM; Ingle AM; Krailo M; Stork LC; Melemed AS; McGovern R; Safgren S; Ames MM; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1505-11. PubMed ID: 17442992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
    Larson RA; Geller RB; Janisch L; Milton J; Grochow LB; Ratain MJ
    Cancer Chemother Pharmacol; 1995; 36(3):204-10. PubMed ID: 7781139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.
    van Groeningen CJ; Leyva A; O'Brien AM; Gall HE; Pinedo HM
    Cancer Res; 1986 Sep; 46(9):4831-6. PubMed ID: 2425959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.